NCT05255666撤回2 期
Phase II Study of the Combination of Liposomal Irinotecan (Nal-IRI) and Pembrolizumab for Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Central Nervous System Disease Control Rate (DCR)
研究概览
简要总结
The study is a phase II with safety lead in, single arm, study using Nal-IRI in combination with pembrolizumab. Nal-IRI will be given IV every 2 weeks starting at 50mg/m2. Pembrolizumab will be given 400mg IV every 6 weeks. Treatment will continue until progression, intolerable side effects or patient/doctor decision to discontinue treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must meet all of the following applicable inclusion criteria to participate in this study:
- •Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
- •Age ≥ 18 years at the time of consent.
- •ECOG Performance Status of 0-1 within 28 days prior to registration.
- •Histological or cytological confirmation of triple-negative breast cancer (TNBC) NOTE: TNBC will be defined as expression of ER<10%, PR< 10% and HER2 negative either by IHC (0, 1+ are negative, 2+ equivocal) or in situ hybridization method (ratio <2.0 is negative). AJCC, 8th edition.
- •Subjects must have brain metastasis; new or progressive with at least one lesion ≥ 5 mm in at least one dimension. NOTE: the number of brain lesions is not limited.
- •Measurable disease according to RECIST 1.1 and/or RANO-BM within 28 days prior to registration.
- •Prior treatment with immunotherapy is allowed. Patients CANNOT have received prior liposomal irinotecan or irinotecan. Patients who received prior sacituzumab govitecan are eligible if without disease progression for at least 16 weeks on therapy and a washout of at least 24 weeks prior to C1D
- •NOTE: No more than 4 prior lines of therapy in the metastatic setting is allowed.
- •Prior cancer treatment including investigational agents must be completed at least 14 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to Grade ≤ 1 or baseline.
- •Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 14 days prior to registration.
- •Hematological
- •Absolute Neutrophil Count (ANC): ≥ 1.5 K/mm3
- •Hemoglobin (Hgb): ≥ 9 g/dL; without erythropoietin dependency and without packed red blood cell (PRBC) transfusion within 2 weeks of registration
- •Platelet Count (PLT): ≥100 000/µL
- •Creatinine OR: ≤1.5 × ULN OR
- •Calculated creatinine clearance: ≥30 mL/min
- •Total Bilirubin: ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN
- •Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT): ≤2.5 × ULN (≤5 × ULN for participants with liver metastases)
- •Albumin: > 30 g/L
- •Coagulation ---International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT): ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
- •Life expectancy of ≥ 12 weeks as assessed by the investigator.
- •Females of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Females of childbearing potential and males must be willing to abstain from heterosexual intercourse or to use an effective method(s) of contraception as outlined in the protocol.
- •As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study (or that legally authorized representative will do so on their behalf).
排除标准
- •Subjects meeting any of the criteria below may not participate in the study:
- •Has a known history of Human Immunodeficiency Virus (HIV) infection. NOTE: No HIV testing is required unless mandated by local health authority.
- •Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. NOTE: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
- •Has a known history of active TB (Bacillus Tuberculosis).
- •Has an active infection requiring systemic therapy.
- •Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
- •Has received colony-stimulating factors (e.g., granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony stimulating factor [GM-CSF]) within 2 weeks prior to the first dose of study drug.
- •Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to C1D
- •Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.
- •Has had an allogenic tissue/solid organ transplant.
- •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
- •Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
- •Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- •Is pregnant or breastfeeding.
研究组 & 干预措施
Pembrolizumab + Liposomal Irinotecan
Experimental
- 400 mg of pembrolizumab intravenously on Day 1 of each Cycle (Cycle is 42 days)
- 50 mg/m^2 of liposomal irinotecan (Nal-IRI) intravenously every 2 weeks of each Cycle (Cycle is 42 days)
干预措施: Pembrolizumab (Drug)
Pembrolizumab + Liposomal Irinotecan
Experimental
- 400 mg of pembrolizumab intravenously on Day 1 of each Cycle (Cycle is 42 days)
- 50 mg/m^2 of liposomal irinotecan (Nal-IRI) intravenously every 2 weeks of each Cycle (Cycle is 42 days)
干预措施: Liposomal Irinotecan (Drug)
结局指标
主要结局
Central Nervous System Disease Control Rate (DCR)
时间窗: 6 months
-DCR is defined as the rate of complete response (CR) + rate of partial response (PR), and rate of stable disease (SD) at 6 months and will be determined as per modified Neuro-Oncology-Brain Metastases (RANO-BM) criteria
次要结局
- Safety and tolerability as measured by the number of grade 3 and 4 adverse events(Through 90 days after completion of treatment (estimated to be 9 months))
- Central Nervous System Objective Response Rate (ORR)(Through completion of treatment (estimated to be 6 months))
- Non-Central Nervous System Objective Response Rate (ORR)(Through completion of treatment (estimated to be 6 months))
- Progression Free Survival (PFS)(Through completion of follow-up (estimated to be 3 years and 6 months))
- Overall Survival (OS)(Through completion of follow-up (estimated to be 3 years and 6 months))
研究者
相似试验
已完成
1 期
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid TumorsRefractory Solid TumorsNCT03810742PharmaEngine44
已完成
2 期
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or ChemoradiotherapyHead & Neck CancerNCT03712397National Health Research Institutes, Taiwan59
尚未招募
2 期
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic CancerPancreatic CancerNCT06700603Rui-hua Xu, MD, PhD48
招募中
2 期
NALIRIFOX as Induction Therapy in LAPCPancreatic Ductal AdenocarcinomaNCT06467565The First Affiliated Hospital with Nanjing Medical University20
招募中
2 期
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT06341296West China Hospital86